Sodium iodide
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1976
- First approval year
- 1976
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Sodium iodide
- Molecular weight
- 149.89
- Structure (SMILES)
These details could not be displayed.
- fdy 5301
- Fdy-5301
- FDY-5301
- Iodide
- Iodide (as sodium iodide)
- IODIDE (AS SODIUM IODIDE) [VANDF]
- iodide as sodium iodide
- iodide as sodium iodide vandf
- nsc 77388
- NSC-77388
- sodium iodide
- Sodium iodide
- SODIUM IODIDE [EP MONOGRAPH]
- SODIUM IODIDE [HSDB]
- SODIUM IODIDE [II]
- SODIUM IODIDE [JAN]
- SODIUM IODIDE [MART.]
- SODIUM IODIDE [MI]
- SODIUM IODIDE [USP MONOGRAPH]
- SODIUM IODIDE [VANDF]
- Sodium iodide [WHO-DD]
- sodium iodide ep monograph
- sodium iodide hsdb
- sodium iodide ii
- sodium iodide jan
And 5 more, listed on the interactive page.
- CAS registry numbers
- 7681-82-5
- ChEMBL ID
- CHEMBL1644695
- InChIKey
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M
- PubChem compound IDs
- 5238
- RxNorm IDs (RxCUI)
- 9884
- FDA ingredient codes (UNII)
- F5WR8N145C
- Applicant
- BRACCO
- Approval date
- 2 May 1957
- Application number
- NDA010929
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
Administration routes
- Oral
- Condition
- Myocardial Infarction
- Highest recorded phase
- 2
- Condition identifier
- EFO:0008583
- Subject identifier
- D009203
- Condition
- ST Elevation Myocardial Infarction
- Highest recorded phase
- 2
- Condition identifier
- EFO:0008585
- Subject identifier
- D000072657
- Condition identifier
- EFO_0000612
- Highest recorded phase
- 2
- Condition identifier
- EFO_0008583
- Highest recorded phase
- 3
- Condition identifier
- EFO_0008585
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002087
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002120
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004781
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005005
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005068
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005086
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005140
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005203
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0006247
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0008170
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008233
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0009693
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0010150
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0011962
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0015486
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0015686
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0015759
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0015760
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0017827
- Highest recorded phase
- 1
And 3 more, listed on the interactive page.
- Event
- arthralgia
- Reports
- 3
- Reporting signal score
- 9.67522
- Event
- asthenia
- Reports
- 2
- Reporting signal score
- 11.2342
- Event
- condition aggravated
- Reports
- 1
- Reporting signal score
- 10.9502
- Event
- contrast media allergy
- Reports
- 6
- Reporting signal score
- 18.6416
- Event
- contrast media reaction
- Reports
- 4
- Reporting signal score
- 8.65326
- Event
- dizziness
- Reports
- 3
- Reporting signal score
- 14.5457
- Event
- drug hypersensitivity
- Reports
- 787
- Reporting signal score
- 2,862.27
- Event
- drug tolerance
- Reports
- 6
- Reporting signal score
- 14.9971
- Event
- fatigue
- Reports
- 8
- Reporting signal score
- 14.7408
- Event
- gastric bypass
- Reports
- 4
- Reporting signal score
- 9.97167
- Event
- headache
- Reports
- 5
- Reporting signal score
- 14.9295
- Event
- hyperleukocytosis
- Reports
- 6
- Reporting signal score
- 21.2297
- Event
- injection site pain
- Reports
- 1
- Reporting signal score
- 8.63422
- Event
- iodine allergy
- Reports
- 14
- Reporting signal score
- 76.6343
- Event
- kidney perforation
- Reports
- 2
- Reporting signal score
- 12.4737
- Event
- nausea
- Reports
- 17
- Reporting signal score
- 8.01634
- Event
- placental insufficiency
- Reports
- 5
- Reporting signal score
- 17.2313
- Event
- pneumonia
- Reports
- 1
- Reporting signal score
- 11.8829
- Event
- polyhydramnios
- Reports
- 4
- Reporting signal score
- 11.1323
- Event
- pyrexia
- Reports
- 3
- Reporting signal score
- 11.5226
- Event
- renal aplasia
- Reports
- 4
- Reporting signal score
- 13.7679
- Event
- symmetrical drug-related intertriginous and flexural exanthema
- Reports
- 3
- Reporting signal score
- 9.26886
- Event
- urethral valves
- Reports
- 2
- Reporting signal score
- 9.11648
- Event
- urinary ascites
- Reports
- 2
- Reporting signal score
- 11.8373
Trial references
- NCT03470441
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- Yes
- Heavy atoms
- 2
- Molecular formula
- INa
- Monoisotopic mass
- 149.89424
- Natural product
- No
- Recorded assays
- 363
- Active assays
- 2
Active assay types
- Confirmatory
Related records
Trials (14)
- A Randomised Controlled Trial of Iodide Supplementation in Preterm Infants Follow-up at 2 Years
- A Study of Acute Myocardial Infarction Using FDY-5301
- Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
- Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
- Evaluation in STEMI Patients Using FDY-5301
- Evaluation of FDY-5301 in Major Trauma Patients in ICU
- Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma
- LISA-study : Levothyroxin in Nodular Goiter
- MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
- MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
- Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer
- Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery
- Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma
- Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer
In development for (4)
- Acute myocardial infarction Phase 2
- Keratoconus Phase 3
- Myocardial infarction Phase 2
- ST-elevation myocardial infarction Phase 2